ACVBP-R regimen: Difference between revisions
Created page with "__NOTOC__ {{SI}} {{CMG}}; {{AE}} {{AV}} {{SK}} ==Overview== {{PAGENAME}} refers to a chemotherapy regimen consisting of (drugs) used in the treatment of (condition). =..." |
No edit summary |
||
| (6 intermediate revisions by the same user not shown) | |||
| Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{AV}} | {{CMG}}; {{AE}} {{AV}} | ||
{{SK}} | {{SK}} Adriamycin-Cytoxan-Vindesine-Bleomycin-Prednisone-Rituximab Regimen | ||
==Overview== | ==Overview== | ||
{{PAGENAME}} refers to a [[chemotherapy regimen]] consisting of | {{PAGENAME}} refers to a [[chemotherapy regimen]] consisting of [[doxorubicin]], [[cyclophosphamide]], [[vindesine]], [[bleomycin]], [[prednisone]], and [[rituximab]] used in the treatment of [[non-Hodgkin lymphoma]]. | ||
==Regimen== | ==Regimen== | ||
{{chemo|A|Doxorubicin (Adriamycin)}} | |||
{{chemo|C|Cyclophosphamide}} | |||
{{chemo|V|Vindesine}} | |||
{{chemo|B|Bleomycin}} | |||
{{chemo|P|Prednisone}} | |||
{{chemo|R|Rituximab}} | |||
==Indications== | |||
* [[Diffuse large B-cell lymphoma]]<ref name="pmid22118442">{{cite journal| author=Récher C, Coiffier B, Haioun C, Molina TJ, Fermé C, Casasnovas O et al.| title=Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial. | journal=Lancet | year= 2011 | volume= 378 | issue= 9806 | pages= 1858-67 | pmid=22118442 | doi=10.1016/S0140-6736(11)61040-4 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22118442 }}</ref> | |||
==References== | ==References== | ||
Latest revision as of 14:08, 11 March 2015
|
WikiDoc Resources for ACVBP-R regimen |
|
Articles |
|---|
|
Most recent articles on ACVBP-R regimen Most cited articles on ACVBP-R regimen |
|
Media |
|
Powerpoint slides on ACVBP-R regimen |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on ACVBP-R regimen at Clinical Trials.gov Trial results on ACVBP-R regimen Clinical Trials on ACVBP-R regimen at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on ACVBP-R regimen NICE Guidance on ACVBP-R regimen
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on ACVBP-R regimen Discussion groups on ACVBP-R regimen Patient Handouts on ACVBP-R regimen Directions to Hospitals Treating ACVBP-R regimen Risk calculators and risk factors for ACVBP-R regimen
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for ACVBP-R regimen |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Synonyms and keywords: Adriamycin-Cytoxan-Vindesine-Bleomycin-Prednisone-Rituximab Regimen
Overview
ACVBP-R regimen refers to a chemotherapy regimen consisting of doxorubicin, cyclophosphamide, vindesine, bleomycin, prednisone, and rituximab used in the treatment of non-Hodgkin lymphoma.
Regimen
ADoxorubicin (Adriamycin)
CCyclophosphamide
VVindesine
BBleomycin
PPrednisone
RRituximab
Indications
References
- ↑ Récher C, Coiffier B, Haioun C, Molina TJ, Fermé C, Casasnovas O; et al. (2011). "Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial". Lancet. 378 (9806): 1858–67. doi:10.1016/S0140-6736(11)61040-4. PMID 22118442.